Trial Profile
A Study Assessing Persistence Rate and Predictors of Persistence of TNF-alpha Inhibitors and Interleukin 12/23 Inhibitor in all Psoriasis Patients in the Real-World Settings in Hungary
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 27 Feb 2018 New trial record